Centogene N.V. (CNTG)
Stock Price:
$13.30 USD
-3.77 (-22.09%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
After-hours: $13.39 +0.09 (0.68%) Jul 10, 7:53 PM
Key Info
| Market Cap |
264.16M |
| Revenue (ttm) |
54.81M |
| Net Income (ttm) |
-23.21M |
| Shares Out |
19.86M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 10, 2020 |
| Last Price |
$13.30 |
| Previous Close |
$17.07 |
| Change ($) |
-3.77 |
| Change (%) |
-22.09% |
| Day's Open |
13.75 |
| Day's Range |
13.20 - 13.92 |
| Day's Volume |
2,248,162 |
| 52-Week Range |
7.80 - 28.71 |
More Stats
| Market Cap |
264.16M |
| Enterprise Value |
248.28M |
| Earnings Date (est) |
Apr 29, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
19.86M |
| Float |
3.44M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
0.75 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
5.63% |
| Payout Ratio |
n/a |
| Shares Short |
94,467 |
| Short Ratio |
2.62 |
| Short % of Float |
0.71% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
17.77 |
| PS Ratio |
4.82 |
| PB Ratio |
7.96 |
| Revenue |
54.81M |
| Operating Income |
-20.99M |
| Net Income |
-23.21M |
| Free Cash Flow |
14.86M |
| Net Cash |
15.87M |
| Net Cash / Share |
0.80 |
| Gross Margin |
46.69% |
| Operating Margin |
-38.30% |
| Profit Margin |
-42.30% |
| FCF Margin |
27.12% |
| ROA |
-15.02% |
| ROE |
-62.25% |
| ROIC |
-32.30% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
2 |
| Overweight |
1 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$22.50*
(69.17% upside)
Low
21.0
Current: 13.30
High
25.0
Target: 22.50
*Average 12-month USD price target from 4 stock analysts.
Financial Performance
Financial numbers in millions EUR.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 48.78 | 40.48 | 31.69 | 27.67 |
| Revenue Growth | 20.51% | 27.74% | 14.53% | - |
| Gross Profit | 22.78 | 20.54 | 16.75 | 14.81 |
| Operating Income | -18.68 | -10.61 | -4.46 | -4.94 |
| Net Income | -20.66 | -10.97 | -5.35 | -5.22 |
| Shares Outstanding | 19.86 | 19.86 | - | - |
| Earnings Per Share | -1.30 | -0.80 | -0.40 | -25.00 |
| Operating Cash Flow | -7.78 | -4.58 | -4.34 | 1.39 |
| Capital Expenditures | 21.00 | -8.71 | -15.50 | -7.74 |
| Free Cash Flow | 13.23 | -13.29 | -19.84 | -6.35 |
| Cash & Equivalents | 41.10 | 9.22 | 3.16 | 0.00 |
| Total Debt | 26.97 | 19.68 | 19.34 | - |
| Net Cash / Debt | 14.13 | -10.46 | -16.18 | 0.00 |
| Assets | 118 | 76.67 | 55.49 | - |
| Liabilities | 57.65 | 49.39 | 38.75 | - |
| Book Value | 59.86 | 27.28 | 16.74 | - |
Numbers in millions EUR, except per-share numbers.
Company Details
| Full Name |
Centogene N.V. |
| Country |
Germany |
| Employees |
440 |
| CEO |
Arndt Rolfs |
Stock Information
| Ticker Symbol |
CNTG |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: CNTG |
Description
Centogene N.V. operates as a commercial-stage rare disease company in Europe, Middle East, North America, Latin America, and Asia Pacific. The company operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform based on data repository, which includes epidemiologic, phenotypic, and genetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. The company has collaborative research agreement with Shire related for HAE Kininogen assay mass spectrometry testing and screening. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.